(89 days)
The Randox Rheumatoid Factor Latex-Enhanced Immunoturbidimetric Test Kit is an invitro diagnostic reagent for the quantitative determination of rheumatoid factors (RF) in human serum. This test kit may be used to facilitate the detection and diagnosis of Rheumatoid Arthritis. RF have also been observed in the serum of patients with systemic lupus erythematosus, hepatitis, liver cirrhosis and syphilis. However, in these conditions the RF titre is much lower than in rheumatoid arthritis.
This test kit must be used by suitably qualified personnel under appropriate laboratory conditions.
RF calibrator and RF positive control are for use in the calibration and quality control of RF latex-enhanced immunoturbidimetric assays.
Not Found
The provided document is an FDA 510(k) clearance letter for the Rheumatoid Factor Latex-Enhanced Immunoturbidimetric Test Kit. This letter approves the device for marketing based on its substantial equivalence to a predicate device. It does not contain the detailed study data, acceptance criteria, or performance metrics in a format that allows me to populate the requested table directly.
The FDA 510(k) summary (which is a separate document often submitted with the clearance letter, but not provided here) typically describes the performance data and the comparison to the predicate device. Without that specific summary or the full study report, I cannot provide the detailed information requested regarding acceptance criteria, reported performance, sample sizes, ground truth methodology, or expert qualifications.
Therefore, I cannot fulfill your request to describe the acceptance criteria and the study that proves the device meets them using only the provided text. The provided text is a regulatory clearance document, not a scientific study report.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with its wings spread, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" are arranged in a circular pattern around the eagle. The eagle is composed of three thick, curved lines that form the shape of the bird's body and wings. The text is in a simple, sans-serif font.
SEP - 9 1997
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Dr. Pane Armstrong Regulatory Affairs Randox Laboratories Limited Biochemical Manufacturers Ardmore, Diamond Road, Crumlin, Co. Antrim, United Kingdom, BT29 4QY
Re : K972220/S1 Trade Name: Rheumatoid Factor Latex-Enhanced Immunoturbidimetric Test Kit Regulatory Class: II Product Code: DHR Dated: August 11, 1997 August 13, 1997 Received:
Dear Dr. Armstrong:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Druq, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual reqistration, listing of devices, qood manufacturing practice, labelinq, and prohibitions aqainst misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affectinq your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP requlation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Reqister. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Requlations.
{1}------------------------------------------------
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
510(k) Number (if known): __ Not Known
Rheumatoid Factor Latex-Enhanced Device Name:
Immunoturbidimetric Test Kit
Indications For Use:
The Randox Rheumatoid Factor Latex-Enhanced Immunoturbidimetric Test Kit is an invitro diagnostic reagent for the quantitative determination of rheumatoid factors (RF) in human serum. This test kit may be used to facilitate the detection and diagnosis of Rheumatoid Arthritis. RF have also been observed in the serum of patients with systemic lupus erythematosus, hepatitis, liver cirrhosis and syphilis. However, in these conditions the RF titre is much lower than in rheumatoid arthritis.
This test kit must be used by suitably qualified personnel under
appropriate laboratory conditions.
RF calibrator and RF positive control are for use in the calibration and quality control of RF latex-enhanced immunoturbidimetric assays.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evalua
Yotter Maler
Prescription Use (Per 21 CFR 801.109)
Over-The-Counter Use
(Optional Format 1-2-96)
§ 866.5775 Rheumatoid factor immunological test system.
(a)
Identification. A rheumatoid factor immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the rheumatoid factor (antibodies to immunoglobulins) in serum, other body fluids, and tissues. Measurement of rheumatoid factor may aid in the diagnosis of rheumatoid arthritis.(b)
Classification. Class II (performance standards).